Anabolic androgenic steroids (AAS), simply called “androgens”, represent the most widespread drugs used to enhance performance and appearance in a sporting environment. High-dosage and/or long-term AAS administration has been associated frequently with significant alterations in the cardiovascular system, some of these with severe endpoints. The induction of a prothrombotic state is probably the most life-threatening consequence, suggested by numerous case reports in AAS-abusing athletes, and by a considerable number of human and animal studies assessing the influence of exogenous androgens on hemostasis. Despite over fifty years of research, data regarding the thrombogenic potential of exogenous androgens are still scarce. The main reason is the limited possibility of conducting human prospective studies. However, human observational studies conducted in athletes or patients, in vitro human studies, and animal experiments have pointed out that androgens in supraphysiological doses induce enhanced platelet activity and thrombopoiesis, leading to increased platelet aggregation. If this tendency overlaps previously existing coagulation and/or fibrinolysis dysfunctions, it may lead to a thrombotic diathesis, which could explain the multitude of thromboembolic events reported in the AAS-abusing population. The influence of androgen excess on the platelet activity and fluid–coagulant balance remains a subject of debate, urging for supplementary studies in order to clarify the effects on hemostasis, and to provide new compelling evidence for their claimed thrombogenic potential.

Taurine is a semi-essential, the most abundant free amino acid in the human body, with a six times higher concentration in platelets than any other amino acid. It is highly beneficial for the organism, has many therapeutic actions, and is currently approved for heart failure treatment in Japan. Taurine has been repeatedly reported to elicit an inhibitory action on platelet activation and aggregation, sustained by in vivo, ex vivo, and in vitro animal and human studies. Taurine showed effectiveness in several pathologies involving thrombotic diathesis, such as diabetes, traumatic brain injury, acute ischemic stroke, and others. As human prospective studies on thrombosis outcome are very difficult to carry out, there is an obvious need to validate existing findings, and bring new compelling data about the mechanisms underlying taurine and derivatives antiplatelet action and their antithrombotic potential. Chloramine derivatives of taurine proved a higher stability and pronounced selectivity for platelet receptors, raising the assumption that they could represent future potential antithrombotic agents. Considering that taurine and its analogues display permissible side effects, along with the need of finding new, alternative antithrombotic drugs with minimal side effects and long-term action, the potential clinical relevance of this fascinating nutrient and its derivatives requires further consideration.

No abstract

The drug dependence especially opioid dependence,represents at moment a very challenging therapeutic domain,even that huge steps-methadone,buprenorphine,naltrexone-had been discovered. The fact that almost 50% of all drug-induced psychosis results during the progess of disease to various forms of schizophrenia is as well an undeniable truth.

No abstract

IntroductionSchizophrenia (SZ) remains the most challenging psychiatric pathology at moment despite huge efforts made with the scope to achieve a clear better understanding of its etiology and pathophysiology. at least 1% of world populations suffers from this disease.ObjectiveAn avalanche of recent studies reveals the massive importance of glutamate abnormalities which appear in the debut phases and contribute essentially to the further development of severe symptoms. Old, classical and peculiar dopamine hypothesis starts day by day to become less feasible.AimsBased on a better understanding will be more efficient to develop more efficient therapeutic products. Based on more accuracy and real understanding of GABA and Glutamate roles in the pathophysiology of SZ is possible for staring more efficient therapiesMethodsIn this sense we realised a thematical research study from vast bibliographical resources.between 2000–2009 all basic research and clinic-pathological studies, indexed on Pubmed, Medline and Wiley Science Library had been reviewed.ResultsSimple mechanical appreciation shows, unfortunately, that at moment dopamine theory still dominates the etio-pathology of this major psychiatric syndrome. In fact dopamine variations are secondary to glutamate dysfunctions. We don’t need to forget that most of actual treatments-second generation of antipsychotics- had been produced on basis of dopamine hyperfunction theory. The importance of glutamate and GABA deficiencies, which offer a more clear and logical explanation of pathology seen in SZ, cannot be considered as secondary to hypodopaminergic frontality or to hyperdopaminergic inputs from nucleus accumbens.

IntroductionIt is well known that actual mechanisms which explain depression are very exhaustive and at same time extremely limited. Among these ones, it had been given the priority, maybe too quick, to serotonin hypothesis. Even so, the actual SSRI and SRNI classes doesn’t do. really, a lot in alleviating the course of the disease. Recent randomised clinical trials and clinic -epidemiological studies support the idea that something more effective must be offered. On the other side addiction reveals more and more in depth correlations with all major psychiatric disorders.ObjectivesIt is possible to develop in the close future new chemical products which could act in more effective way for the reduction or even cancelling of the symptoms determined by the alteration of major neurotransmitters-, GABA and glutamate.AimsBased on huge interconnection which exists between depression and drug dependence at various levels-especially through the effects exerted by particular anti depressant and some of anti craving medications, it is possible to evaluate the impact which some new pharmaceutical compounds -derivated from glutamate type of receptor NMDA-might exert upon various types of depression elicited by patients with associated drug dependence.MethodsHad been realised a thematical reanalysis of the studies published on Medline, EMBASE and OVID about this subject.ResultsThe conclusion of the studies reveals the huge potential represented by treatment with some types of NMDA antagonists-Ketamine. The putative site of action is prefrontal cortex and is had been proved highly efficient in MDD patients.

No abstract